FINWIRES · TerminalLIVE
FINWIRES

Top Midday Gainers

-- Aehr Test Systems (AEHR) said Thursday that it has received a $41 million follow-on production order from an unnamed hyperscale customer for package-level burn-in of custom artificial processor ASICs.

Shares jumped 14%, with intraday trading volume rising to more than 6.7 million from a daily average of about 2.2 million.

Myseum (MYSE), a social media and technology company, said late Wednesday it is operating under the new name Myseum.AI Inc., effective April 15. As part of the rebrand, the company's core technology platform will integrate its proprietary artificial intelligence technology into messaging and social media platforms.

Shares catapulted 155% as intraday trading volume surged to over 182.4 million from a daily average of about 447,000.

JPMorgan upgraded the shares of Allogene Therapeutics (ALLO) to neutral from underweight.

Shares climbed 6% as intraday trading volume advanced to over 16.7 million from a daily average of roughly 9 million.

Price: $83.10, Change: $+9.88, Percent Change: +13.49%

Related Articles

Asia

Shakti Pumps (India) Invests INR100 Million in EV Mobility Unit

Shakti Pumps (India) (NSE:SHAKTIPUMP, BOM:531431) said it has invested 100 million Indian rupees in its wholly owned subsidiary Shakti EV Mobility by subscribing to 10 million equity shares, according to a Tuesday filing to the Indian stock exchanges.Shares of the company rose 1% in Wednesday's trade.With this, Shakti Pumps' total investment in the EV mobility unit has increased to 650 million Indian rupees, the filing said.The investment is aimed at supporting business expansion of the subsidiary, it added.

$BOM:531431$NSE:SHAKTIPUMP
Asia

Challenger's Fiscal 2026 Q3 Update Missed Consensus Across Key Life Metrics, Jarden Says

Challenger's (ASX:CGF) fiscal 2026 third-quarter update missed consensus across key Life metrics, with FM outflows significantly worse than expected, driven by institutional equity mandate attrition in both Australian and global equities, according to a Tuesday note by Jarden.The firm's redemption of all CGFPC notes on May 25 simplifies the capital structure, reduces the AT1 coupon burden, and is earnings-per-share accretive.Jarden sees balanced risk/reward for Challenger in the future, with catalysts including capital management flexibility from the Australian Prudential Regulation Authority reform, as well as expanding retirement partnerships across superfunds.It lowered its fiscal 2026 sales forecast to reflect weaker institutional fixed-term sales, partially offset by higher retail annuity sales as partnerships come online.The investment firm retained its neutral rating on Challenger and raised the price target to AU$8.70 per share from AU$8.60 per share.

$ASX:CGF
Asia

Proya Cosmetics 2025 Profit Down 4%, Revenue Slips 2%

Proya Cosmetics (SHA:603605) posted 2025 attributable net profit of 1.50 billion yuan, down 3.5% from 1.55 billion yuan the previous year.Earnings per share slid to 3.80 yuan from 3.92 yuan, according to a Wednesday filing with the Shanghai bourse.Operating revenue declined 1.7% year over year to 10.6 billion yuan from 10.8 billion yuan.Shares of the cosmetics maker were up over 1% in recent trade.

$SHA:603605